No abstract

No abstract

No abstract

Conclusion and relevance DOR would be beneficial in those patients with CNS disorders due to EFV and high viral load (>100 000 copies) or in polymedicated patients because of the lower profile of interactions. In the remaining cases, there are alternatives already available in the hospital (following recommendations of the GESIDA guidelines).

According to the delta values, there could be clinically relevant differences among them. Conclusion and relevance NMA showed no significant differences in OS between PC-pembrolizumab and carboplatin-gemcitabine, PC-motesanib, PC-necitumumab, PC-olaratumab and pembrolizumab in umSNSCLC, but there could be clinically relevant differences.